NZ511034A - Methods of downmodulating the immune response to therapeutic proteins - Google Patents
Methods of downmodulating the immune response to therapeutic proteinsInfo
- Publication number
- NZ511034A NZ511034A NZ511034A NZ51103499A NZ511034A NZ 511034 A NZ511034 A NZ 511034A NZ 511034 A NZ511034 A NZ 511034A NZ 51103499 A NZ51103499 A NZ 51103499A NZ 511034 A NZ511034 A NZ 511034A
- Authority
- NZ
- New Zealand
- Prior art keywords
- immune response
- downmodulating
- methods
- therapeutic proteins
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A composition comprising a therapeutic protein, such as factor VIII, which promotes hemostasis and an agent, such as CTLA4, which inhibits the interaction of a costimulatory molecule on an antigen presenting cell and its cognate ligand on a T cell, wherein said composition is a composition for the treatment of a hemostatic disorder which reduces the development and/or progression of an immune response to the therapeutic protein.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15817898A | 1998-09-21 | 1998-09-21 | |
PCT/US1999/021991 WO2000016801A1 (en) | 1998-09-21 | 1999-09-21 | Methods of downmodulating the immune response to therapeutic proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ511034A true NZ511034A (en) | 2004-03-26 |
Family
ID=22566971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ511034A NZ511034A (en) | 1998-09-21 | 1999-09-21 | Methods of downmodulating the immune response to therapeutic proteins |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1115423A1 (en) |
JP (1) | JP2002526455A (en) |
KR (1) | KR20010085830A (en) |
CN (1) | CN1331602A (en) |
AU (1) | AU761206B2 (en) |
BR (1) | BR9913991A (en) |
CA (1) | CA2343916A1 (en) |
CZ (1) | CZ20011021A3 (en) |
EA (1) | EA005236B1 (en) |
HK (1) | HK1039059A1 (en) |
HU (1) | HUP0103960A3 (en) |
IL (1) | IL142069A0 (en) |
LT (1) | LT4920B (en) |
LV (1) | LV12768B (en) |
MX (1) | MXPA01002898A (en) |
NO (1) | NO20011412L (en) |
NZ (1) | NZ511034A (en) |
PL (1) | PL346796A1 (en) |
SI (1) | SI20626A (en) |
WO (1) | WO2000016801A1 (en) |
ZA (1) | ZA200103156B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
DE60118362T2 (en) * | 2000-05-19 | 2007-05-24 | The Center for Blood Research, Inc., Boston | METHOD FOR TREATING HEMOSTATIC INTERFERENCE BY SOLUBLE P-SELECTIN |
EP1636579A4 (en) * | 2003-06-10 | 2011-10-05 | Smiths Detection Inc | Sensor arrangement |
GB201508024D0 (en) * | 2015-05-11 | 2015-06-24 | Haemostatix Ltd | Haemostatic compositions |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5171569A (en) | 1985-03-15 | 1992-12-15 | National Research Development Corporation | Factor IX preparations uncontaminated by plasma components or pox virus |
US4868112A (en) | 1985-04-12 | 1989-09-19 | Genetics Institute, Inc. | Novel procoagulant proteins |
US5422260A (en) | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
FR2657884B1 (en) | 1990-02-05 | 1994-09-02 | Tm Innovation | PROCESS FOR THE PREPARATION OF HUMAN FACTOR VIII AND FACTOR VIII ANALOGS. |
US5661008A (en) | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
KR100238712B1 (en) | 1991-06-27 | 2000-01-15 | 스티븐 비. 데이비스 | Method for regulating the immune response using b7 binding molecules and il4-binding molecules |
WO1993009804A1 (en) | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation |
US5744446A (en) | 1992-04-07 | 1998-04-28 | Emory University | Hybrid human/animal factor VIII |
US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
US5663060A (en) | 1992-04-07 | 1997-09-02 | Emory University | Hybrid human/animal factor VIII |
US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
WO1996005860A1 (en) * | 1994-08-19 | 1996-02-29 | Novo Nordisk A/S | A method of treating a patient with a biologically active compound |
JPH10507758A (en) * | 1994-10-19 | 1998-07-28 | ジェネティック セラピー,インコーポレイテッド | Gene therapy with simultaneous administration of adenovirus and immunosuppressive drugs |
US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
PT892643E (en) * | 1996-03-20 | 2002-09-30 | Univ Emory | METHODS FOR INHIBITING AN IMMUNITY RESPONSE BLOCKING THE GP39 / CD40 AND CTLA4 / CD28 / B7 CIRCUITS AND USES FOR THE EFFECT |
ATE356634T1 (en) * | 1997-01-10 | 2007-04-15 | Biogen Idec Inc | METHOD FOR THERAPEUTIC ADMINISTRATION OF ANTI-CD40L AGENTS |
TR199903141T2 (en) * | 1997-06-20 | 2000-09-21 | Biogen, Inc. | CD154 blockade therapy for therapeutic protein blocker syndrome. |
US8099877B2 (en) | 2009-11-06 | 2012-01-24 | Hexagon Metrology Ab | Enhanced position detection for a CMM |
-
1999
- 1999-09-21 CZ CZ20011021A patent/CZ20011021A3/en unknown
- 1999-09-21 EP EP99969339A patent/EP1115423A1/en not_active Withdrawn
- 1999-09-21 EA EA200100385A patent/EA005236B1/en not_active IP Right Cessation
- 1999-09-21 PL PL99346796A patent/PL346796A1/en not_active Application Discontinuation
- 1999-09-21 CA CA002343916A patent/CA2343916A1/en not_active Abandoned
- 1999-09-21 BR BR9913991-0A patent/BR9913991A/en not_active IP Right Cessation
- 1999-09-21 CN CN99813510A patent/CN1331602A/en active Pending
- 1999-09-21 JP JP2000573762A patent/JP2002526455A/en not_active Withdrawn
- 1999-09-21 KR KR1020017003611A patent/KR20010085830A/en not_active Application Discontinuation
- 1999-09-21 MX MXPA01002898A patent/MXPA01002898A/en unknown
- 1999-09-21 WO PCT/US1999/021991 patent/WO2000016801A1/en not_active Application Discontinuation
- 1999-09-21 AU AU60578/99A patent/AU761206B2/en not_active Ceased
- 1999-09-21 IL IL14206999A patent/IL142069A0/en unknown
- 1999-09-21 SI SI9920084A patent/SI20626A/en not_active IP Right Cessation
- 1999-09-21 HU HU0103960A patent/HUP0103960A3/en unknown
- 1999-09-21 NZ NZ511034A patent/NZ511034A/en unknown
-
2001
- 2001-03-20 NO NO20011412A patent/NO20011412L/en not_active Application Discontinuation
- 2001-04-18 ZA ZA200103156A patent/ZA200103156B/en unknown
- 2001-04-20 LT LT2001045A patent/LT4920B/en not_active IP Right Cessation
- 2001-04-20 LV LVP-01-62A patent/LV12768B/en unknown
-
2002
- 2002-01-10 HK HK02100157.7A patent/HK1039059A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2343916A1 (en) | 2000-03-30 |
AU761206B2 (en) | 2003-05-29 |
LT4920B (en) | 2002-06-25 |
MXPA01002898A (en) | 2002-06-04 |
HK1039059A1 (en) | 2002-04-12 |
LV12768B (en) | 2002-06-20 |
EP1115423A1 (en) | 2001-07-18 |
HUP0103960A2 (en) | 2002-02-28 |
BR9913991A (en) | 2001-07-03 |
KR20010085830A (en) | 2001-09-07 |
LT2001045A (en) | 2002-01-25 |
IL142069A0 (en) | 2002-03-10 |
WO2000016801A1 (en) | 2000-03-30 |
PL346796A1 (en) | 2002-02-25 |
CN1331602A (en) | 2002-01-16 |
HUP0103960A3 (en) | 2003-09-29 |
SI20626A (en) | 2002-02-28 |
ZA200103156B (en) | 2002-07-18 |
JP2002526455A (en) | 2002-08-20 |
NO20011412D0 (en) | 2001-03-20 |
NO20011412L (en) | 2001-05-16 |
EA005236B1 (en) | 2004-12-30 |
AU6057899A (en) | 2000-04-10 |
WO2000016801A9 (en) | 2000-10-26 |
CZ20011021A3 (en) | 2001-10-17 |
EA200100385A1 (en) | 2001-10-22 |
LV12768A (en) | 2001-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0643726T3 (en) | Human p53 protein peptides for use in compositions that induce human T cell response and human p53 protein | |
EA200000445A1 (en) | METHODS OF TREATING THE CONDITION OF HYPERCOAGULATION OR ACQUIRED INSUFFICIENCY OF PROTEIN C | |
FI953442A0 (en) | Freeze-dried beads containing gonadotropin | |
TR199903331T2 (en) | Farnesil protein transferase inhibitors. | |
ATE517922T1 (en) | STABILIZED SINGLE-DOMAIN ANTIBODIES IN A PHARMACEUTICAL COMPOSITION DESIGNED FOR INHALATION | |
FI961621A0 (en) | Substituted tetra- and pentapeptide inhibitors of protein: farnesyl transferase | |
CY1111863T1 (en) | OPTIONS AGAINST DEATH RECEPTOR 4 (DR4) AND THEIR USES | |
WO1998022136A3 (en) | Stable lyophilized pharmaceutical substances from monoclonal or polyclonal antibodies | |
UA95438C2 (en) | Bispecific antibodies substituting for functional proteins | |
TR200000015T2 (en) | Compounds and methods | |
IL160641A0 (en) | Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them | |
IL127558A0 (en) | Hepatocyte growth factor receptor agonists and uses thereof | |
CA2413190A1 (en) | Methods for treating rheumatic diseases using a soluble ctla4 molecule | |
DK0836485T3 (en) | Cascade-polymer complexes, processes for their preparation, and pharmaceutical agents containing them | |
DK0915974T3 (en) | Modified tie-2 receptor ligands | |
CY1109868T1 (en) | CD81 PROFESSIONAL SUBSCRIPTION PROTECTOR C | |
WO2001068708A3 (en) | Human and humanized fap-alpha-specific antibodies | |
AU6832398A (en) | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof | |
DE69434384D1 (en) | METALKOMPLEXBILDNER | |
ATE234111T1 (en) | THERAPEUTIC USES OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BLEEDING CAUSED BY TRAUMA | |
DK0845998T3 (en) | Immunotherapy drugs containing antibodies that specifically recognize the MHCII antigen in a patient to be treated | |
WO1997029199A3 (en) | Prostate specific antigen peptides and uses thereof | |
EP1064005A4 (en) | Urokinase plasminogen activator receptor as a target for diagnosis of metastases | |
MX9101958A (en) | AMINOSULFONYL UREA ACAT INHIBITORS | |
NZ511034A (en) | Methods of downmodulating the immune response to therapeutic proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ASS | Change of ownership |
Owner name: AMERICAN RED CROSS, US Free format text: OLD OWNER(S): AMERICAN RED CROSS; GENETICS INSTITUTE, INC. Owner name: GENETICS INSTITUTE, US Free format text: OLD OWNER(S): AMERICAN RED CROSS; GENETICS INSTITUTE, INC. |
|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |